ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 1, 2013, Pages 159-165

  De Dosso, Sara ^a   Zanellato, Elena ^b   Nucifora, Martina ^b   Boldorini, Renzo ^c   Sonzogni, Angelica ^d   Biffi, Roberto ^d   Fazio, Nicola ^d   Bucci, Eraldo ^e   Beretta, Ottavio ^b   Crippa, Stefano ^b   Saletti, Piercarlo ^a   Frattini, Milo ^b  

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^b INSTITUTE OF PATHOLOGY   (Switzerland)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e IRCCS MULTIMEDICA   (Italy)

Author keywords

Adjuvant; Cisplatin; ERCC1; Gastric

Indexed keywords

CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; PROTEIN P53; THYMIDYLATE SYNTHASE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA DAMAGE; DOWN REGULATION; EXCISION REPAIR CROSS COMPLEMENTING GENE 1; FEMALE; FOLLOW UP; GENE EXPRESSION REGULATION; GENE MUTATION; GENE SEQUENCE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STOMACH ADENOCARCINOMA; SURVIVAL TIME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COHORT STUDIES; DNA-BINDING PROTEINS; ENDONUCLEASES; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; RETROSPECTIVE STUDIES; STOMACH; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84879793400     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2181-2     Document Type: Article

References (45)

1. Songun I, Putter H, Kranenbarg EM et al (2010) Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 11:439-449
2. Cunningham D, Allum WH, Stenning SP et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11-20
3. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN et al (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725-730
4. Macdonald J, Smalley S, Haller D, et al (2009) Chemoradiation of resected gastric cancer: a 10-year follow-up of the phase III trial INT0116 (SWOG 9008). J Clin Oncol 27(15 suppl), abstr 4515
5. Okines AF, Cunningham D (2010) Multimodality treatment for localized gastro-oesophageal cancer. Ann Oncol 21(Suppl 7):vii286-vii293
6. Hermans J, Bonenkamp JJ, Boon MC et al (1993) Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 11:1441-1447
7. Earle CC, Maroun JA (1999) Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomized trials. Eur J Cancer 35:1059-1064
8. Mari E, Floriani I, Tinassi A, Buda A, Belfiglio M, Valentini M et al (2000) Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomized trials. Ann Oncol 11:837-843
9. Panzini I, Gianni L, Fattori PP et al (2002) Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori 88:21-27
10. Paoletti X, Oba K, Burzykowski T et al (2010) Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group. JAMA 303:1729-1737
11. Sakuramoto S, Sasako M, Yamaguchi T et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810-1820
12. Sasako M, Sakuramoto S, Katai H et al (2011) Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 29:4387-4393
13. Bang YJ, Kim YW, Yang HK et al (2012) Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379:315-321
14. Metzger R, Leichman CG, Danenberg KD et al (1998) ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16:309-316
15. Matsubara J, Nishina T, Yamada Y et al (2008) Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br J Cancer 98:832-839
16. Yeh KH, Shun CT, Chen CL et al (1998) High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy. Cancer 82:1626-1631
17. Hua D, Huang ZH, Mao Y et al (2007) Thymidylate synthase and thymidine phosphorylase gene expression as predictive parameters for the efficacy of 5-fluorouracil-based adjuvant chemotherapy for gastric cancer. World J Gastroenterol 13:5030-5034
18. Choi J, Lim H, Nam DK et al (2001) Expression of thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. Br J Cancer 84:186-192
19. Lenz HJ, Leichman CG, Danenberg KD et al (1996) Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 14:176-182
20. Chin KV, Ueda K, Pastan I et al (1992) Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 255:459-462
21. Lowe SW, Ruley HE, Jacks T et al (1993) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967
22. Findlay M, Cunningham D, Norman A et al (1994) A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 5:609-616
23. van Krieken JH, Jung A, Kirchner T et al (2008) KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 453:417-431
24. Olaussen KA, Dunant A, Fouret P et al (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983-991
25. Zucali AP, Giovannetti E, Destro A et al (2011) Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin. Clin Cancer Res 17:2581-2590
26. Perrone F, Oggionni M, Birindelli S et al (2003) TP53, p14ARF, p16INK4a and H-ras gene molecular analysis in intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses. Int J Cancer 105:196-203
27. Rosell R, Taron M, Ariza A et al (2004) Molecular predictors of response to chemotherapy in lung cancer. Semin Oncol 31(1 Suppl 1):20-27
28. Dabholkar M, Bostick-Bruton F, Weber C et al (1992) ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 84:1512-1517
29. Reed E (2005) ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res 11:6100-6102
30. Liu Y, Ling Y, Liu B et al (2010) Use of ERCC1 expression in resected specimen to predict survival in both patients with gastric cancer treated with surgery followed by oxaliplatin-based adjuvant chemotherapy and in those receiving surgery alone. Gastrointestinal Cancers Symposium abstr 29
31. Kim KH, Kwon HC, Oh SY et al (2011) Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy. Biomarkers 16:74-82
32. Baek SK, Kim SY, Lee JJ et al (2006) Increased ERCC expression correlates with improved outcome of patients treated with cisplatin as an adjuvant therapy for curatively resected gastric cancer. Cancer Res Treat 38:19-24
33. Bamias A, Karina M, Papakostas P et al (2010) A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. Cancer Chemother Pharmacol 65:1009-1021
34. Kwon HC, Roh MS, Oh SY et al (2007) Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 18:504-509
35. Wang Z, Chen JQ, Liu JL et al (2012) Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review. BMC Gastroenterol 12:137
36. Yeh KH, Shun CT, Chen CL et al (1998) High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy. Cancer 82:1626-1631
37. Kim JS, Kim MA, Kim TM et al (2009) Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival. Br J Cancer 100:732-738
38. Choi J, Lim H, Nam DK et al (2001) Expression of thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. Br J Cancer 84:186-192
39. Hua D, Huang ZH, Mao Y et al (2007) Thymidylate synthase and thymidine phosphorylase gene expression as predictive parameters for the efficacy of 5-fluorouracil-based adjuvant chemotherapy for gastric cancer. World J Gastroenterol 13:5030-5034
40. Chin KV, Ueda K, Pastan I et al (1992) Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 255:459-462
41. Boku N, Chin K, Hosokawa K et al (1998) Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. Clin Cancer Res 4:1469-1474
42. Yeh KH, Shun CT, Chen CL et al (1999) Overexpression of p53 is not associated with drug resistance of gastric cancers to 5-fluorouracil-based systemic chemotherapy. Hepatogastroenterology 46:610-615
43. Giatromanolaki A, Stathopoulos GP, Koukourakis MI et al (2001) Angiogenesis and apoptosis-related protein (p53, bcl-2, and bax) expression versus response of gastric adenocarcinomas to paclitaxel and carboplatin chemotherapy. Am J Clin Oncol 24:222-226
44. Kikuyama S, Inada T, Shimizu K et al (2001) p53, bcl-2 and thymidine phosphorylase as predictive markers of chemotherapy in patients with advanced and recurrent gastric cancer. Anticancer Res 21:2149-2153
45. Díez M, Medrano MJ, Gutierrez A et al (2000) P53 protein expression in gastric adenocarcinoma. Negative predictor of survival after postoperative adjuvant chemotherapy. Anticancer Res 20:3929-3933